What Is Polymyalgia Rheumatica References

  1. Mackie SL. Polymyalgia rheumatica: pathogenesis and management. Clinical Medicine [serial online]. August 2013;13(4):398-400.
  2. Michet Clement J, Matteson Eric L. Polymyalgia rheumatica BMJ 2008; 336 :765
  3. Kyle V, Hazelman BL. Editorial: Stopping steroids in polymyalgia rheumatica and giant cell arteritis. BMJ 1990;300:344–5. As cited in - Charlton R. Polymyalgia rheumatica and its links with giant cell arteritis. Clin Med 2008;8:498–501.
  4. Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long?Ann Rheum Dis 1983;42:374–8.
  5. Dasgupta B., Borg FA., Hassan N. et al. on behalf of the BSR and BHPR Standards, Guidelines and Audit Working Group; BSR and BHPR guidelines for the management of polymyalgia rheumatica, Rheumatology, Volume 49, Issue 1, 1 January 2010, Pages 186–190.
  6. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Annals of the Rheumatic Diseases. 1989;48(8):662-666.
  7. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004 Apr; 33 (5): 289-93 As cited in - Schmidt J, Warrington K. Polymyalgia Rheumatica and Giant Cell Arteritis in Older Patients. Drugs & Aging [serial online]. August 2011;28(8):651-666.
  8. Mandell BF. Polymyalgia rheumatica: Clinical presentation is key to diagnosis and treatment. Cleve Clin J Med 2004; 71 : 489-95. And Mackie SL, Hughes R, Walsh M, Day J, Newton M, Pease C, et al. “An impediment to living life”: Why and how should we measure stiffness in polymyalgia rheumatica? PLoS One 2015; 10 : e0126758. As cited in - Milchert M, Brzosko M. Diagnosis of polymyalgia rheumatica usually means a favourable outcome for your patient. Indian Journal Of Medical Research [serial online]. May 2017;145(5):593-600.
  9. Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis?. Rheumatology (Oxford). 2016;55(1):66-70.
  10. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years. Arthritis Rheum 2003; 48 : 3522-31. As cited in - Milchert M, Brzosko M. Diagnosis of polymyalgia rheumatica usually means a favourable outcome for your patient. Indian Journal Of Medical Research [serial online]. May 2017;145(5):593-600.
  11. Cimmino MA. Genetic and environmental factors in polymyalgia rheumatica Annals of the Rheumatic Diseases 1997;56:576-577.
  12. Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol 2000; 18:S9-11; PMID:10948749
  13. Chung T-Y, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97: 672-80 And Salvarani C, Macchioni PL, Tartoni PL, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987; 5: 205-15 As cited in - Salvarani C, Macchioni L, Olivieri I, Cantini F, Boiardi L. Diagnosis and Management of Polymyalgia Rheumatica/Giant Cell Arteritis. Biodrugs[serial online]. January 1998;9(1):25-32.
  14. Salvarani C, Gabriel S, Hunder GG. Distal extremity swelling with pitting edema in polymyalgia rheumatica: Report of nineteen cases. Arthritis Rheum 1996; 39: 73-80.
  15. Muratore, F., Salvarani, C., & Macchioni, P. (2018). Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica. Reumatismo, 70(1), 18-22.
  16. Turkcapar N, Demir O, Atli T, Kopuk M, Turgay M, Kinikli G, et al. Late onset rheumatoid arthritis: clinical and laboratory comparisons with younger onset patients. Arch Gerontol Geriatr. 2006;42:225–31.
  17. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36:1286-1294. As cited in Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999;159:577-84.
  18. Chuang T-Y, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10- year epidemiologic and clinical study. Ann Intern Med. 1982;97:672-680. As cited in Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999;159:577-84.
  19. A. Emamifar, Rannveig Gildberg-Mortensen, S. Andreas Just, N. Lomborg, R. Asmussen Andreasen, and I. M. Jensen Hansen, “Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study,” International Journal of Rheumatology, vol. 2015, Article ID 783709, 5 pages, 2015.
  20. R. M. R. Pereira, J. F. de Carvalho, and E. Canalis, “Glucocorticoid-induced osteoporosis in rheumatic diseases,” Clinics, vol. 65, no. 11, pp. 1197–1205, 2010. As cited in - A. Emamifar, Rannveig Gildberg-Mortensen, S. Andreas Just, N. Lomborg, R. Asmussen Andreasen, and I. M. Jensen Hansen, “Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study,” International Journal of Rheumatology, vol. 2015, Article ID 783709, 5 pages, 2015.